|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
|   |

 |
|

|  |
| --- |
|  |
| PSNC Newsletter |
| Friday 22nd April 2022 |

 |
|  |
|

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  | This newsletter from PSNC is sent on Mondays, Wednesdays and Fridays. It contains important information for those that work in the community pharmacy sector.In this update: Flu vac letter for 2022/23 published; PSNC factsheet on accessing NHSmail on mobile devices; new MHRA Drug Safety Update; expected increase of DOACs.Annual flu letter for 2022/23 publishedThe Department of Health and Social Care (DHSC), the UK Health Security Agency (UKHSA) and NHS England and NHS Improvement (NHSE&I) have **today** jointly published the annual flu vaccination programme letter for the 2022/23 flu vaccination season. The letter reconfirms the eligible cohorts for the 2022/23 season and the vaccines which will be reimbursable under the 2022/23 Community Pharmacy Seasonal Influenza Vaccination Advanced Service.[**Find out more**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=197bc855c3&e=d19e9fd41c)PSNC factsheet about NHSmail on mobile devicesPSNC has published a factsheet for community pharmacy teams explaining how to access the shared NHSmail inbox within the Outlook mobile app. The app provides quick and easy access to NHSmail, and enables contractors to choose how and when they would like to be notified about incoming emails.The one-page factsheet provides a step-by-step guide on how to set-up NHSmail within Outlook apps and how to adjust notification settings.[**Read the factsheet**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=9f81a1bcaa&e=d19e9fd41c) April 2022 MHRA Drug Safety UpdateThe Medicines and Healthcare products Regulatory Agency (MHRA) has published a new Drug Safety Update containing updates on the findings of a safety study on the risks of Pregabalin useduring pregnancy, COVID-19 vaccines, medicines recalls and more. [**Read the April 2022 MHRA Drug Safety Update**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=dd0df3ee44&e=d19e9fd41c)New Commissioning Guidance for DOACsPharmacy teams may see an increased number of prescriptions for direct oral anticoagulants (DOACs) following the recent publication of [**NHS Commissioning Guidance**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=c6cf55ee3f&e=d19e9fd41c) for DOACs. This guidance recommends that clinicians should, where clinically appropriate, use edoxaban (Lixiana) for the treatment of patients newly diagnosed with AF. The new guidance is part of plans by NHSE&I to accelerate the uptake of direct oral anticoagulants (DOACs), which could see over 600,000 more patients with atrial fibrillation (AF) benefit over the next three years, preventing tens of thousands of stroke events.Pharmacy teams may also see a greater number of patients currently on warfarin and other DOACs switched to edoxaban in the coming months. This is consistent with the updated [**AF guideline**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=90d28d1585&e=d19e9fd41c) from the National Institute for Health and Care Excellence (NICE) which recommends DOACs as the preferred anticoagulant for patients with AF, unless contraindicated, not tolerated or not suitable.  |  |
|  |  |  |

 |

 |
|

|  |  |  |
| --- | --- | --- |
|

|  |
| --- |
| Pharmaceutical Services Negotiating Committee  **Graphical user interface  Description automatically generated** **Graphical user interface  Description automatically generated** 14 Hosier Lane, London, EC1A 9LQTel: 0203 1220 810 | Email: **info@psnc.org.uk**  |
|  |

 |

 |

